WallStreetZenWallStreetZen

NASDAQ: SRDX
Surmodics Inc Stock Forecast, Predictions & Price Target

Analyst price target for SRDX

Based on 2 analysts offering 12 month price targets for Surmodics Inc.
Min Forecast
$43.00+25.07%
Avg Forecast
$57.00+65.79%
Max Forecast
$71.00+106.52%

Should I buy or sell SRDX stock?

Based on 2 analysts offering ratings for Surmodics Inc.
Buy
Strong Buy
0 analysts 0%
Buy
2 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SRDX stock forecasts and price targets.

SRDX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-05-02
lockedlocked$00.00+00.00%2024-05-01

1 of 1

Forecast return on equity

Is SRDX forecast to generate an efficient return?
Company
N/A
Industry
-0.02%
Market
17.32%

Forecast return on assets

Is SRDX forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

SRDX revenue forecast

What is SRDX's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$123.5M-13.58%
Avg 2 year Forecast
$141.8M-0.83%
Avg 3 year Forecast
$168.9M+18.17%
SRDX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SRDX revenue growth forecast

How is SRDX forecast to perform vs Medical Devices companies and vs the US market?
Company
0.62%
Industry
8.36%
Market
9.65%
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SRDX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SRDX vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
SRDX$34.38$57.00+65.79%Buy
NNOX$8.43$18.00+113.52%Strong Buy
MXCT$4.54$8.67+90.90%Strong Buy
BVS$6.37$8.50+33.44%Strong Buy
PACB$1.87$5.17+176.31%Buy

Surmodics Stock Forecast FAQ

Is Surmodics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: SRDX) stock is to Buy SRDX stock.

Out of 2 analysts, 0 (0%) are recommending SRDX as a Strong Buy, 2 (100%) are recommending SRDX as a Buy, 0 (0%) are recommending SRDX as a Hold, 0 (0%) are recommending SRDX as a Sell, and 0 (0%) are recommending SRDX as a Strong Sell.

If you're new to stock investing, here's how to buy Surmodics stock.

What is SRDX's revenue growth forecast for 2024-2026?

(NASDAQ: SRDX) Surmodics's forecast annual revenue growth rate of 0.62% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.36%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.65%.

Surmodics's revenue in 2024 is $142,963,000.On average, 2 Wall Street analysts forecast SRDX's revenue for 2024 to be $1,761,765,960, with the lowest SRDX revenue forecast at $1,761,295,380, and the highest SRDX revenue forecast at $1,762,250,800. On average, 2 Wall Street analysts forecast SRDX's revenue for 2025 to be $2,021,768,540, with the lowest SRDX revenue forecast at $2,018,060,940, and the highest SRDX revenue forecast at $2,025,490,400.

In 2026, SRDX is forecast to generate $2,409,055,880 in revenue, with the lowest revenue forecast at $2,402,182,560 and the highest revenue forecast at $2,415,929,200.

What is SRDX's forecast return on assets (ROA) for 2024-2026?

(NASDAQ: SRDX) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is SRDX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year SRDX price target, the average SRDX price target is $57.00, with the highest SRDX stock price forecast at $71.00 and the lowest SRDX stock price forecast at $43.00.

On average, Wall Street analysts predict that Surmodics's share price could reach $57.00 by May 2, 2025. The average Surmodics stock price prediction forecasts a potential upside of 65.79% from the current SRDX share price of $34.38.

What is SRDX's forecast return on equity (ROE) for 2024-2026?

(NASDAQ: SRDX) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.